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When nanoparticles/proteins are infused into the brain, they are often transported to distal
sites in a manner that is dependent both on the characteristics of the infusate and the region
targeted. We have previously shown that adeno-associated virus (AAV) is disseminated
within the brain by perivascular ﬂow and also by axonal transport. Perivascular distribution
usually does not depend strongly on the nature of the infusate. Many proteins, neutral
liposomes and AAV particles distribute equally well by this route when infused under
pressure into various parenchymal locations. In contrast, axonal transport requires receptor-
mediated uptake of AAV by neurons and engagement with speciﬁc transport mechanisms
previously demonstrated for other neurotropic viruses. Cerebrospinal ﬂuid (CSF) represents
yet another way in which brain anatomy may be exploited to distribute nanoparticles broadly
in the central nervous system. In this study, we assessed the distribution and perivascular
transport of nanoparticles of different sizes delivered into the parenchyma of rodents and
CSF in non-human primates.
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INTRODUCTION
The movement of macromolecules and nanoparticles within the
brain is not a simple process and no single mechanism is entirely
responsible for the dissemination of such substances. Three main
routes of distribution have been described: rapid perivascular ﬂow,
rapid paravascular ﬂow of cerebrospinal ﬂuid (CSF), and slow
axonal transport of viral particles both anterograde and retro-
grade. With tools at hand today, we can isolate and interrogate
each pathway substantially independently of the others.
Our initial forays into this area arose from investigations into
the therapeutic utility of adeno-associated viral (AAV) vector for
the treatment of Parkinson’s disease (Bankiewicz et al., 2000). It
was soon apparent that pressurized convection-enhanced deliv-
ery (CED) infusions of AAV2-hAADC into the primate striatum
resulted in pronounced transgene expression in the globus pal-
lidus. At the time, we assumed that this was due to a perivascular
mechanism, and subsequent studies have conﬁrmed that this is
indeed the case. We showed in rat experiments that perivas-
cular distribution is greatly inﬂuenced by heart rate and is
extremely rapid (Hadaczek et al., 2006). Infusion of AAV parti-
cles or liposomes into rat striatum revealed rapid movement along
perivascular tracts leading from the site of infusion into the globus
pallidus. This kind of acute distribution is vectorial. Other parts of
the basal ganglia, such as substantia nigra, were not the recipient
of this type of rapid transport, suggesting that speciﬁc vascular
tracts are required to enable this process. More recent studies of
parenchymal infusion of liposomes visible by real-time magnetic
resonance imaging (MRI) have revealed that rapid convective ﬂow
is the primary means by which parenchymal infusions can cover
volumes of tissue several fold greater than the volume of infusate
(Krauze et al., 2005a, 2006, 2009).
In contrast to this rapid distribution of a variety of infusates,
the axonal transport of AAV particles occurs over a more extended
timeframe. Although AAV particles can indeed be distributed
perivascularly in anatomically restricted domains, it is the ability
of AAV to be taken up by neurons and transported over long dis-
tances that has excited intense interest. We showed some years ago
that AAV2 is transported intact from primate thalamus to cortex
where release of AAV2 particles results in widespread transduc-
tion of neurons in a number of cortical layers to which thalamic
neurons project (Kells et al., 2009). Similarly, we described antero-
grade axonal transport of AAV2 in basal ganglia in primates (Kells
et al., 2012) and in rodents (Ciesielska et al., 2011). Anterograde
transport is not ubiquitous among AAV serotypes. For example,
AAV6 is transported in a retrograde direction and we are actively
exploring the repertoire of available serotypes in this regard.
More recently, we have explored CSF infusions as a way to dis-
tribute nanoparticles throughout the primate brain (Samaranch
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et al., 2013). Both AAV7 and AAV9, infused via intrathecal injec-
tion (lumbar puncture) or into cisterna magna (CM) injection,
direct robust transgene expression throughout spinal cord, brain-
stem, cerebellum, and cortex. As we discuss below, the pattern of
transgene expression is consistent with the paravascular ﬂow of
CSF through these regions. We found also that this phenomenon
is not restricted to AAV7 and AAV9. Fluorescent micelles are also
extensively distributed through the paravascular pathways deep
into the brain.
Due to the presence of the blood–brain barrier (BBB), distri-
bution of therapeutic agents within the central nervous system
(CNS) is a major problem in drug delivery. In this study, given our
current focus, we provide a more detailed view on the distribu-
tion of nanoparticles within the parenchyma of rodents and CSF
of non-human primates (NHPs), as alternative routes for deliv-
ering therapeutic agents in vivo. In particularly, we demonstrate
how nanoparticles of different properties and sizes can be rapidly
distributed to remote regions within the brain, either propelled
by an exogenous pressurized delivery and/or by the endogenous
ﬂow of the CSF. Each mechanism displays unique anatomical tar-
geting properties that may be exploited to therapeutic effect. This
emerging repertoire of routes for infusate distribution also carries
implications for delivery of other types of therapeutic nanoparti-
cles. It should be noted that, given the size and “simpler” axonal
connectivity of the rodent’s brain relative to that of primates, we
generally perform parenchymal injections in rodents and then
validate CSF delivery the primate.
MATERIALS AND METHODS
ANIMALS
To investigate the transport of AAV particles, 12 Sprague–Dawley
(SD) rats (∼250–350 g) received a unilateral infusion into the
thalamus of AAV2-green ﬂuorescent protein (GFP) or AAV6-
GFP. To examine the perivascular transport of larger particles
ﬁve SD animals received a single thalamic infusion of ﬂuores-
cently labeled DiIC18-liposomes (1 μM). To determine whether
any ultra-structural changes had occurred after intra-parenchymal
pressurized delivery, two animals were processed for electron
microscopy (EM) and infused with phosphate buffered saline
(PBS) alone with one additional animal serving as a non-infused
naïve control. Perivascular transport of AAV particles infused into
the CSF (cisterna magna) was examined in four NHPs (Macaca
mulatta) that received a single injection of either AAV7 or AAV9-
GFP (n = 2/serotype; Samaranch et al., 2013). To evaluate the
transport of larger particles in NHP, one NHP received a single
injection of Oregon Green (OG) labeled micelles into the CM.
No differences in body weight and/or adverse symptoms were
observed throughout the study. All procedures were carried out
in accordance with the UCSF Institutional Animal Care and Use
Committee (IACUC) and the Animal Care and Use Committee
(ACUC) at Valley Biosystems Inc.
INFUSATES
AAV2-GFP (1.3 vg/mL × 1013 vg/mL), AAV6-GFP (1.2 vg/mL ×
1013 vg/mL), AAV7-GFP (2.0 vg/mL × 1013 vg/mL), AAV9-
GFP (1.8 vg/mL × 1013 vg/mL) were manufactured by the
ResearchVector Core facility at Children’sHospital of Philadelphia
(∼20–25 nm in size; Matsushita et al., 1998). Liposomes
were ﬂuorescently labeled with membrane-bound DiIC18
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlo-
rate as described (∼65 nm in size; Krauze et al., 2006). 3-
helix micelles are self-assembling amphiphilic peptide-polymer
conjugates (∼15 nm in size; Dong et al., 2012). The micelle-
forming amphiphile is denoted as dC18-1CW(P2K)-P750. This
amphiphile was labeled with the ﬂuorescent agent, OG, and the
product denoted as dC18-1CW(P2K)-OG (Dong et al., 2012).
10 mg dC18-1coi(P2K)-P750 and 1 mg of dC18-1CW(P2K)-OG
were dissolved in 0.5 mL of methanol in a glass vial and the sol-
vent was evaporated in vacuum oven for 3 h. The dried ﬁlm was
rehydrated with 2 mL of 25 mM phosphate buffer, pH 7.4, and the
solution was stirred for 16 h to allow assembly of OG-conjugated
ﬂuorescent 3-helix micelles. The micelle solution was washed to
remove any unincorporated OG and concentrated by spin ﬁltra-
tion. The concentrate was washed with water and lyophilized
to obtain OG labeled 3-helix micelles. Fluorescent micelle solu-
tion was prepared by directly dissolving the lyophilized fraction in
phosphate buffer. Micelles at 6 mg/mL were used for in vivo injec-
tions. Fluorescence was visualized at 488 nm on a Zeiss Axiomat
microscope.
INFUSIONS
Rats were anesthetized with isoﬂurane (Baxter, Deerﬁeld, IL,
USA) and placed in a stereotactic frame (David Kopf Instruments,
Tujunga, CA,USA). A 1-cm longitudinal incision was made on the
skin overlaying the skull and a burr-hole was drilled at the follow-
ing coordinates for targeting the thalamus (AP: −2.8, ML: +1.6,
DV:−5.5 mm). A fused silica (Polymicro Technologies, USA) with
a 1 mm stepped cannula (0.1 mm internal diameter) was used to
deliver a total volume of 12μL in experiments investigatingAAV2,
AAV6 and EM,whereas, animals infused with liposomes received a
total volumeof 5μL at a rate of 0.5μL/min (for all infusates). Total
length of infusion procedure lasted either 24 or 10 min, respec-
tively, plus a ﬁnal 2 min period prior to cannulae retraction to
reduce reﬂux of infusate.
Non-human primate were sedated with ketamine/xylazine and
placed in a prone position in a stereotactic frame with the head
ﬂexed. A 3 mL syringe was manually guided into the CM until
CSF was aspirated into the syringe. Once the correct position of
the needle was veriﬁed, 2 mL of infusate was infused into the CM
at a rate of 0.5 μL/min. The duration of the infusion procedure
was approximately 4 min with a 2 min waiting period prior to
withdrawal of the needle.
TISSUE PROCESSING
Animals were subjected to necropsy either at 3 weeks (rats)
or 6 weeks (NHP) after vector infusion or 4 h after micelle
delivery (NHP) and transcardially perfused with PBS followed
by 4% paraformaldehyde (PFA)/PBS. Brains were harvested,
post-ﬁxed in 4% PFA/PBS for 24–48 h and cryoprotected
in 30% sucrose. All post-ﬁxed brains were cut into 40 μm
serial sections that were then processed for immunohistochem-
istry. Liposome-treated animals were sacriﬁced 30 min after
infusion with an overdose of sodium pentobarbital solution
and their brains were immediately frozen in dry-ice cooled
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isopentane. Every second 40 μm section was collected and
viewed with a Zeiss microscope with a ﬁlter appropriate for Cy-3
ﬂuorescence.
ELECTRON MICROSCOPY
Animals used for EM were transcardially perfused with 0.1 M
Sodium Cacodylate (pH 7.4) buffer solution and then ﬁxed with
a mixture of 2% Glutaraldehyde, 1% PFA and 0.1 M Sodium
Cacodylate. PBS-infused animals were used as controls and the
thalamus was carefully dissected and embedded in epoxy resin.
Tissue was cut into 1 μm thick sections with a diamond knife
(1.5 mm wide blade at a 45◦ angle; Diatome, USA).
IMMUNOPEROXIDASE STAINING
A polyclonal antibody against GFP (rabbit anti-GFP,
www.millipore.com, Cat. #06-896) was used for immuno-
detection of the transgene in animals that received AAV infusions.
Brieﬂy, sections were washed with PBS (3 min × 5 min), quenched
for endogenous peroxidase activity in 1% H2O2/30% ethanol for
30 min, and then washed brieﬂy in PBS/1% Tween [phosphate
buffered saline including Tween (PBST)]. Sections were blocked
in Background Sniper® (Biocare Medical, BS966G) for 30 min
and incubated overnight at 4◦C with anti-GFP antibody (1:400)
or anti-CD31 (Abcam mouse anti-CD31, clone JC/70A; 1:200) in
Da Vinci® green diluent (Biocare Medical, PD900). After washing
in PBST, sections were incubated for 1 h in Mach-3-rabbit-
probe (Biocare Medical, RP531L) at room temperature (RT),
washed again and incubated inMach-3-rabbit-HRPpolymer (Bio-
care Medical, RH531L) 1 h at RT. After incubation, sections
were washed in PBST and developed with 3,3′-diaminobenzidine
(DAB) for 1 min (DAB Peroxidase Substrate Kit, Vector Laborato-
ries). DAB-processed sections were washed in PBS and mounted
on frosted slides.
RESULTS
AAV SEROTYPES INFLUENCE AXONAL TRANSPORT
The use of AAV vectors encoding ﬂuorescent reporter proteins,
such as GFP, permits us to explore anatomical connections in vivo
by measuring transgene expression at the site of injection and
tracking the expression pattern in distal regions. Although axonal
transport of viruses is a well-known phenomenon, we were the
ﬁrst to demonstrate that AAV2 not only undergoes anterograde
transport but viral particles can apparently be released intact from
nerve terminals to transduce other neurons far from the original
site of vector infusion in a pattern reﬂective of known axonal pro-
jection pathways. We have demonstrated this in the rodent brain
(Ciesielska et al., 2011) and in NHP (Kells et al., 2009). Not all
AAV serotypes undergo anterograde transport like AAV2. AAV6,
for example, is transported exclusively in a retrograde direction in
rodents (Salegio et al., 2013). We initially observed this in a com-
parison of thalamic infusion of AAV2 with AAV6. In this study,
we observed gene transfer throughout all layers of the neocortex
(I–VI), including those in pre-frontal regions distal from the site of
injection (Figure 1). However, the diverse reciprocal connectivity
of the thalamus with cortex made deﬁnitive analysis difﬁcult. By
targeting regions with “simpler” anatomical connections such as
the striatum, we could more conﬁdently determine directionality
of axonal transport. In rodent striatum, both AAV2 and AAV6
transduce only neurons. AAV2 transduces parts of the basal gan-
glia to which striatal neurons project, such as substantia nigra
pars reticulata (SNr) but does not transduce neurons that project
to the striatum such as neurons from the substantia nigra pars
compacta (SNc). In contrast, AAV6 transduces SNc, but not SNr,
neurons after striatal infusion of AAV6. Moreover, striatal AAV6
transduces cortico-striatal neurons whereas AAV2 does not. This
inverse directionality of axonal transport is also seen in NHP
with a minor, but potentially signiﬁcant difference (San Sebas-
tian et al., 2013). AAV6 is not exclusively neurotropic as it is in
rodents, although it is a retrogradely transported vector. Although
the degree of glial transduction was modest, AAV6-GFP never-
theless triggered a brisk cell-mediated immune response to the
non-self transgene, GFP, just as we have seen more intensely with
AAV9 (Ciesielska et al., 2013).
Similarly, retrograde transport of adenovirus has been
described in rat brain (Kuo et al., 1995). One hypothesis is
that differential engagement with molecular machinery that
speciﬁes anterograde or retrograde transport may underlie this
phenomenon. Herpes simplex virus 1 (HSV-1) interacts with
both kinesin and dynein to catalyze anterograde and retro-
grade axonal transport respectively (Diefenbach et al., 2008).
We speculate that these two capacities may be separately
deﬁned in structural differences in AAV2 and AAV6 capsids
(Gao et al., 2004) and possibly by receptor-cell interactions
(Nonnenmacher and Weber, 2012).
AXONAL VERSUS PERIVASCULAR TRANSPORT
Anterograde axonal transport of AAV2 is a relatively slow process
taking at least 6 weeks after delivery to reach an easily detectable
level of transgene expression distal from the site of injection
(Salegio et al., 2013). However, we have established that AAV par-
ticles (∼20–25 nm in size), as well as proteins and liposomes
(∼65 nm in size), can also be distributed very rapidly by non-
axonal means. Perivascular transport of various nanoparticles and
proteins takes place during convective (pressurized) infusions, the
most clear-cut example being distribution of infusates from puta-
men to globus pallidus. We found that the driving mechanism
appears to be arterial pressure (Hadaczek et al., 2006). Increasing
blood pressure in rats undergoing striatal infusions signiﬁcantly
increased distribution of infusates and stopping the heart effec-
tively blocked distribution of infusates beyond the local infusion
site.
We delivered ﬂuorescently labeled liposomes into the thala-
mus of adult rats and evaluated liposomal distribution in the
brain 30 min after delivery. Interestingly, we observed lipo-
somes approximately 2.4 mm rostral and 1.6 mm caudal from
the site of injection (Figure 2). Given that the adult rat brain
is approximately 20 mm in length along the anterior–posterior
(AP) axis (excluding the olfactory bulb; Paxinos and Watson,
1998), we estimate that these liposomes efﬁciently traveled up
to 4 mm on the AP axis, covering 20% of the rat brain.
Consistent with our previous observations, we found ﬂuores-
cently labeled particles surrounding blood vessels (Figure 3),
indicative of perivascular transport. Furthermore, examination
of the macro-environment by EM, revealed the expansion of the
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FIGURE 1 |Transgene distribution after AAV2 andAAV6 delivery. (A–F) Unilateral injection into the thalamus of adult rats of either AAV2 or AAV6 resulted in
widespread expression of GFP transgene in the neocortex and in pre-frontal regions distal to the site of injection. Scale bars:A,D = 5 mm; B,C,E,F = 1 mm.
FIGURE 2 | Early parenchymal distribution of fluorescently
labeled liposomes. (A–E) Acute survival time-point for
liposome-infused animals revealed the rapid spread of ﬂuorescently
labeled liposomes 30 min after delivery into the thalamus. Spread of
ﬂuorescence reached approximately 2.4 mm rostral and 1.6 mm
caudal from the site of infusion, suggesting efﬁcient movement of
these particles throughout the brain after CED. Scale bar:
B–D = 5 mm.
Frontiers in Neuroanatomy www.frontiersin.org March 2014 | Volume 8 | Article 9 | 4
Salegio et al. Distribution of nanoparticles in brain
FIGURE 3 | Perivascular transport of liposomes. (A–F) Examination of
parenchymal tissue 2 mm rostral from the site of infusion showing the
presence of ﬂuorescently labeled liposomes surrounding the lumen of
blood vessels, indicating effective transport of these particles along
perivascular spaces. Scale bars:A,E = 5 mm; C,D = 500 μm; B,F = 1 mm.
extracellular-perivascular space compared to normal non-infused
control tissue (Figure 4). Margin measurements of these pock-
ets revealed that the hydrostatic pressure of CED expanded the
interstitial (Virchow–Robin) space sufﬁcient to accommodate the
distribution of large nanoparticles.
CEREBROSPINAL FLUID (CSF) IS AN EFFICIENT DISTRIBUTOR OF BOTH
AAV AND MICELLES
A third means by which nanoparticles and viruses may be
distributed efﬁciently throughout the brain is via CSF. In previous
studies, we found that intrathecal (cisterna magna) administra-
tion of AAV7 or AAV9 in NHP resulted in extensive transduction
of neuronal and non-neuronal cells throughout the spinal cord,
brainstem and neocortex (Samaranch et al., 2013). The pattern of
distribution throughout white matter was non-uniform and took
the form of rosettes that appeared to surround blood vessels indi-
cated by co-staining against the endothelial marker, CD31, and
GFP transgene (Figure 5). In many cases, the lumen of the vessel
is patent and surrounded by endothelium stained blue and brown
GFP+ cells (mostly astrocytes). This pattern is consistent with the
concept of para-arterial ﬂow of CSF through the brain (Neder-
gaard, 2013) and indicates that brisk ﬂow of CSF from choroid
plexus offers efﬁcient vectorial ﬂow through the cortex and cere-
bellum, as well as into the dorsoventral axis of the spine. Little
transduction of subcortical gray matter is evident in these experi-
ments, suggesting that binding of AAV7 and AAV9 to perivascular
cells is relatively rapid, and the lack of transduction in deeper sub-
cortical structures is a consequence of substantial sequestration of
vector particles from superﬁcial cortical surfaces ﬁrst bathed by
the CSF.
Distribution of relatively inert nanoparticles, demonstrated
thatCSF can easily distribute infusates into the cortical graymatter.
Recently developed ultra-small (∼15 nm in size) sphericalmicelles
(Dong et al., 2012), called “3-helix micelles,” based on amphiphilic
peptide-PEG conjugates where the head-group self-associates into
a 3-helix bundle, were covalently labeled with OG and infused
into the CM of a Rhesus monkey. As shown in Figure 6, ﬂuores-
cent nanoparticles shown in green, ﬁlled the perivascular space
surrounding blood vessels 4 h after cisternal injection of 18 mg
micelles in a 3 mL injection. In contrast to what we observed
with AAV,where transduction was conﬁned to white matter tracts,
brainstem, cerebellum and spinal cord, infusion of micelles gen-
erated prominent perivascular ﬂuorescence not only in brainstem
and cerebellum, but also in the ventral tegmental area (VTA) and
amygdala.
DISCUSSION
Effective therapies for neurological diseases must take account of
the profound anatomical and functional complexity of the brain.
This is doubly so for directly delivered therapies. In this study, we
demonstrated the distribution of nanoparticles of different sizes,
including micelles (∼15 nm in size), AAV (∼20–25 nm) and lipo-
somes (∼65nm),within theCNSof rodents andNHPs. Earlywork
in understanding the distribution of AAV infused under pressure
into the brain parenchyma revealed that the primary means of
distributing vector was via perivascular (Virchow–Robin) spaces
through which CSF ﬂows. It is important to note that simple injec-
tions cannot hope to engage the perivascular system. Specialized
infusion cannulae are required that enable constant pressures to
be exerted at the tip of the cannula such that the interstitial hydro-
static pressure is exceeded and infusate can ﬂow out into the tissue.
Simple needles generate signiﬁcant reﬂux and we introduced a
reﬂux-resistant cannula to counter this tendency (Krauze et al.,
2005c; Varenika et al., 2009). The advent of MRI-guided infusions
further reﬁned our understanding of the mechanics of perivascu-
lar ﬂow and we showed in a number of studies that perivascular
distribution of liposomes was linear with respect to time (Krauze
et al., 2005a, 2006, 2009); the slope of the curve was increased in
myelinated regions (Krauze et al., 2005b) and cessation of infu-
sion prevented further expansion in the volume of distribution.
Moreover, cannula placement is an important variable due to
leakage of infusate into adjacent ventricles and/or white matter
tracts (Yin et al., 2009, 2010a,b). No further increase in volume of
distribution is seen once signiﬁcant leakage occurs, presumably
because of a sharp reduction in infusion pressure. In addition to
a loss in infusion pressure, leakage of infusate into the ventricular
system will lead to unrestricted exposure of the delivered agent
within the CNS. Similarly, white matter tracts will act as a conduit
and greatly distribute infusates throughout, ideal when attempting
global exposure but undesirable when delivering therapeutics to
localized regions.
This requirement for a pressure gradient in parenchymal deliv-
ery is not essential in the delivery of nanoparticles into CSF. The
rate of ﬂow of CSF is so high and the compartment so com-
pliant that injections into CSF of quite large relative volumes
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FIGURE 4 | Expansion of perivascular spaces after CED. PBS-infused
tissue was processed for EM and revealed the expansion of perivascular
spaces after CED. These spaces ranged in size from 11 μm (width) × 3 μm
(height; black arrows;A) and 2.0 μm (w) × 11.5 μm (h; B), as compared to
non-infused, naïve control tissue (C). BV = blood vessel lumen. Scale bar:
1 μm.
FIGURE 5 | Perivascular transport and pattern of transgene
expression. (A–F) Immunostaining against GFP and blood vessels
(CD31; endothelial marker) revealed the presence of GFP-positive cells
surrounding blood vessels. Transgene expression was frequently
observed to form rosette-like patterns in white matter, as demonstrated
in cross-sectional views of blood vessels (B,C,E,F), indicative of
perivascular transport of AAV particles irrespective of the serotype.
Scale bars: A,B,D,E = 500 μm; C,F = 250 μm.
do not cause signiﬁcant increases in intracranial pressure in pri-
mates. We routinely inject up to 6 mL into either CM or lumbar
intrathecal space without complications. The pace of CSF ﬂow
acts as a remarkably effective carrier for nanoparticles such as
AAV or micelles. However, because this approach has remained
relatively unexplored until recently for gene therapy (Snyder et al.,
2011; Federici et al., 2012; Samaranch et al., 2013), the trans-
duction properties of different AAV serotypes in primates is still
unclear. The rosettes of transduction around blood vessels that
we see with AAV7 and AAV9 result primarily from transduction
of perivascular astrocytes. On that basis, one would predict that
a highly neurotropic virus such as AAV2 would be poorly effec-
tive at transducing cells via the CSF route. Conversely, vectors
that transduce astrocytes would be expected to be more efﬁ-
cient at CSF-mediated transduction of the brain. This, however,
remains to be elucidated. It is clear, also, from infusion of non-
viral nanoparticles that rapid distribution of CSF infusates is an
inherently efﬁcient process. In addition to distribution of ﬂuo-
rescent micelles throughout cerebellum, brainstem and cortex, we
saw quantitative distribution into the amygdala and VTA, which
provides encouragement to the idea that chronic drug delivery
to the brain could be mediated by CSF infusion of drug-loaded
micelles.
Axonal transport of AAV has turned out to be an important
discovery. It reminds us forcefully that transduction patterns in
the primate brain are strongly inﬂuenced by neuroanatomy and
that neuronal projections act as efﬁcient conduits through which
intact virions may be transported. Indeed, this same propensity
for neurons to transport other viruses, such as HSV (Diefen-
bach et al., 2008), is well-established. In fact, this phenomenon
has been proposed as a means by which neurological diseases
such as Alzheimer’s (Balin et al., 1998, 2008) and Parkinson’s
disease (Braak et al., 2003) display their characteristic anatom-
ical progression. Thus, it has been proposed that pathogens
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FIGURE 6 | Early distribution of micelles. (A–D) Cisternal injection of
ﬂuorescently labeled micelles (shown in green) indicate the rapid transport of
these particles within different regions of the NHP brain. These micelles ﬁlled
the perivascular space of blood vessels throughout the brain, particularly in
the brainstem (BS), cerebellum (CB), ventral tegmental area (VTA), and
amygdala (AM). Note that these micelles are shown in green (white arrows)
and presence of autoﬂuorescent lipofuscin is shown in red. Scale bars:
A,D = 500 μm; B,C = 250 μm.
gain access to the brain via peripheral neurons and then steadily
progress through interconnected regions. The Braak hypothesis of
Parkinson’s disease, for example, is that the vagal nerve serves
as a primary conduit through which a pathogen could work
its way up through the brainstem to the midbrain and then
to cortical regions (Braak and Braak, 2000). This anatomical
progression is perfectly consistent with staging and progres-
sion of the disease where lesions in speciﬁc nuclei give rise
to stage-speciﬁc symptoms, such as orthostatic hypotension as
sympathetic innervation to the heart atrophies as parkinsonian
degeneration attacks the brainstem. Relevant to the data shown
here, we speculate that, even if disease-compromised neurons
were not able to transport therapeutic agents to the region-of-
interest, an alternative approach would be to design agents that
could be easily transported via the perivascular space, particu-
larly when trying to reach regions of motor control such as the
brainstem.
The in vivo distribution of nanoparticles within the cerebral
cortex, as shown here, invokes certain considerations for gene and
drug therapy. For instance, liposomes, almost three times larger
in size than an AAV particle, efﬁciently covered 20% of the rat’s
brainwithin 30min after delivery, indicating the synergistic poten-
tial of delivering agents through a pressurized system to engage
with the pulsating parenchyma to enhance the amount of brain
volume covered by the agent. AAV, liposomes and micelles are
essentially nanocarriers designed to deliver therapeutic payloads
and in a clinical setting elevation or reduction of a patient’s
heart rate during anesthesia, could play a signiﬁcant role in the
distribution of therapeutic agents (i.e., at least in those deliv-
ered within the parenchyma). Obviously, this requires further
investigation.
In conclusion, advances in biomaterials and development of
nanoparticles are enabling a better understanding of the com-
plex functionality of the central nervous system. Here we describe
the movement of nanoparticles of different composition and size
within the brain of rodents and NHPs. Tools such as ﬂuorescent
reporter proteins in AAV and ﬂuorophore-conjugated nanopar-
ticles have allowed us to better understand some key aspects
associated with perivascular transport, CSF ﬂow and axonal trans-
port. However, even though it is unclear how these routes of
transport would be affected in a diseased-brain, the diverse tools
we have in hand should continue to advance our knowledge in this
area.
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